Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
methydur
- Development stage
- Phase 3
- Lead developer
- Durect
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Methydur is a **sustained-release oral formulation of methylphenidate**, developed using DURECT's proprietary ORADUR technology. It combines both immediate-release and extended-release mechanisms to provide rapid onset (within 2 hours) and prolonged therapeutic effect (8–12 hours) for once-daily dosing. Methydur is indicated for the treatment of **attention deficit hyperactivity disorder (ADHD)** in children and adults, aiming to reduce in-school dosing and risk of social stigma. The ORADUR technology confers abuse-deterrent properties, making extraction of the active ingredient for misuse more difficult. The drug is designed to improve medication adherence, consistency, and avoid impact on nighttime sleep. It was first launched in Taiwan in September 2020 by Orient Pharma, which also oversees manufacturing and regional commercialization efforts. DURECT originated the formulation and licensed global rights to Orient Pharma[1][2][5][7][8].
- Brand names
- MethydurMethydur Sustained Release Capsules
- Other names
- ORADUR-MethylphenidateORADUR-Methylphenidate ERORADURORADUR-ADHD
02
Targets
DAT (Dopamine plasma membrane transport protein)VMAT2 (Vesicular monoamine transporter 2)NET (Norepinephrine Transporter)HTR2B (5-Hydroxytryptamine Receptor 2B)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))
Beyond the preview
Go deeper on methydur.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on methydur.